Prognostic biomarker for acute myeloid leukemia (C1R)
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells. An epigenetic biomarker can support risk assessment.
Epimutation in acute myeloid leukemia (DNMT3A)
About 20% of AML patients have genomic mutations in the gene coding for DNA-methyltransferase 3A (DNMT3A). Recently, it has been shown that genomic mutations in DNMT3A can alternatively be mimicked by epimutations in the same gene.
Biomarker for aplastic anemia and dyskeratosis congenita (PRDM8)
Aplastic anemia is associated with inability to generate mature blood cells resulting in progressive bone marrow failure. Dyskeratosis congenita is associated with impaired telomere maintenance and with clinical features of premature aging. Cygenia provides an epigenetic biomarker to support diagnosis of both diseases.